No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 19 of the 34 quarters in the window, leaving 15 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 35
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T13:21:22.311Z. Latest historical point 2021-11-10. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Cogent Biosciences, Inc. (COGT) stock was $30.87 as of Oct 5, 2026, 4:00 PM EDT, down 0.48% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +95.3% · 3-year avg +45.8%/yr · 5-year avg +28.5%/yr
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies.
Biotechnology · Waltham, MA
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2019-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Nov 6, 2026
31 days away
EPS Estimate
-0.57
Revenue Est.
$750000.00
Last Quarter Results
EPS
$-0.52
vs Estimate
$-0.56
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1COGT | $5.27B | $30.87 | -0.48% | +95.25% | +28.51% | N/A | N/A |
| 2DOCS | $5.35B | $28.58 | +2.33% | -60.81% | -18.23% | N/A | vs COGT |
| 3MMSI | $5.20B | $87.14 | +2.07% | +3.46% | +3.88% | +13.48% | vs COGT |
| 4SRRK | $5.20B | $43.40 | -7.28% | +15.74% | +8.20% | N/A | vs COGT |
| 5ERAS | $5.11B | $14.72 | -0.14% | +503.05% | -8.34% | N/A | vs COGT |
| 6CRSP | $5.53B | $57.34 | +3.45% | -15.29% | -10.97% | N/A | vs COGT |
forward FY estimate
N/A
$0.00
vs Estimate
$1000.00
Consensus Rating
Based on 11 analysts
Average Price Target
$55.82
+80.8% upside
Low
$45.00
Current
$30.87
High
$62.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.59 | $-0.56 | $-0.51 | 6 |
| Quarter ending Dec 2026 | $-0.61 | $-0.56 | $-0.52 | 6 |
| Quarter ending Mar 2027 | $-0.73 | $-0.46 | $-0.10 | 2 |
| Quarter ending Jun 2027 | $-0.61 | $-0.39 | $-0.09 | 2 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-2.39 | $-2.21 | $-2.10 | 8 |
| FY 2027 | $-1.48 | $-1.03 | $-0.36 | 8 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $298913.00 | $750000.00 | $1.08M | 12 |
| Quarter ending Dec 2026 | $2.38M | $5.98M | $8.61M | 7 |
| Quarter ending Mar 2027 | $11.35M | $28.49M | $41.02M | 3 |
| Quarter ending Jun 2027 | $19.97M | $50.11M | $72.13M | 3 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $2.38M | $5.98M | $8.61M | 8 |
| FY 2027 | $168.71M | $292.80M | $411.53M | 9 |
